Emerging Drug Developer: Astex Therapeutics

Astex Therapeutics

Two years after FierceBiotech picked Astex Therapeutics in the UK as one of our Fierce 15 companies to watch, the biotech company is still rolling up impressive licensing deals with big pharma.  

Today Astex announced a $537 million licensing deal with Janssen Pharmaceutica covering FGFR inhibitors for cancer discovered by its fragment-based drug discovery platform. And the deal--which provides $37 million upfront--includes a discovery collaboration for two more cancer targets. 

The new Janssen deal underscores the private company's approach to funding part of its operations through sizeable collaborations sparked by its discovery platform. In today's pact, Janssen R&D arm Ortho Biotech Research & Development agreed to pay for the development costs of the programs while giving Astex an option on co-commercialization rights in the U.S.--a key provision for many developers looking to the future. 

Astex adds to slate of pacts with $537M Janssen deal. Article

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.